Disclaimer: Whilst we always aim to provide accurate information, Recite Me uses machine translation so the translation may not be perfect and we can’t guarantee its accuracy. Myeloma UK accepts no liability for any inaccuracies resulting from the use of this translation tool. The information provided is not meant to replace the advice of your healthcare team. Find out more about this tool at reciteme.com
Join us this insightful online event on the ProMMise-D trial, a new approach aimed at reducing the burden of ocular examinations for patients receiving belantamab mafodotin (belamaf) as part of their treatment for relapsed/refractory multiple myeloma. This platform trial is exploring whether belamaf can be safely administered without frequent ocular exams, potentially reducing healthcare costs, alleviating patient burden, and improving access to treatment across centers.
The ProMMise-D trial arm investigates the use of the Vision Related Anamnestic Tool (VRAT), a clinician-led assessment, to guide belamaf dosing. This webinar will offer an overview of the trial design, assessment methods, and treatment combinations involved.
–
